Over the past decades, the number of patients with dry eye disease (DED) has increased
dramatically. The incidence of DED is higher in Asia than in Europe and North America …

The goals of the TFOS DEWS II Definition and Classification Subcommittee were to create
an evidence-based definition and a contemporary classification system for dry eye disease …

The subcommittee reviewed the prevalence, incidence, risk factors, natural history, morbidity
and questionnaires reported in epidemiological studies of dry eye disease (DED). A meta …

Objective To evaluate the efficacy and safety of NOV03 (perfluorohexyloctane) ophthalmic
drop in patients with dry eye disease (DED) associated with meibomian gland dysfunction …

For the last 20 years, a great amount of evidence has accumulated through epidemiological
studies that most of the dry eye disease encountered in daily life, especially in video display …

Background Dry eye disease (DED) is common; its prevalence around the world varies from
5% to 34%. Its putative pathogenetic mechanisms include hyperosmolarity of the tear film …

Meibomian gland dysfunction (MGD) is the most frequent cause of dry eye disease (DED).
Eyelid inflammation, microbial growth, associated skin disorders as well as potentially …

Meibomian gland dysfunction (MGD) is highly prevalent and is the leading cause of
evaporative dry eye disease (DED). MGD is characterized by a reduction in meibum …

Purpose: To evaluate in a general clinic-based cohort of patients with dry eye disease (DED)
the distribution of patients with aqueous-deficient or evaporative subtype of DED. Methods …

Purpose To evaluate the efficacy and safety of NOV03 (perfluorohexyloctane) ophthalmic
drop for the treatment of signs and symptoms of dry eye disease (DED) associated with …